{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T11:59:00Z","timestamp":1718366340179},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.2169\/internalmedicine.1611-23","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T22:27:05Z","timestamp":1680215225000},"page":"3299-3303","source":"Crossref","is-referenced-by-count":1,"title":["Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice"],"prefix":"10.2169","volume":"62","author":[{"given":"Shun","family":"Tsuchiya","sequence":"first","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japan Community Health Care Organization Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisaku","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei-ji","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Mitsumori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology, Saitama Medical University International Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokohama Municipal Citizen's Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Nerima Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology, Saitama Medical University International Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japan Community Health Care Organization Saitama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Japan"},{"name":"Department of Medical Technology, Kumamoto Health Science University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376: 917-927, 2017.","DOI":"10.1056\/NEJMoa1609324"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30: 1044-1054, 2016.","DOI":"10.1038\/leu.2016.5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34: 2333-2340, 2016.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 36: 231-237, 2018.","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34: 2851-2857, 2016.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ross DM, Masszi T, G\u00f3mez Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol 144: 945-954, 2018.","DOI":"10.1007\/s00432-018-2604-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35: 298-305, 2017.","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 91: 869-874, 2016.","DOI":"10.1002\/ajh.24423"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wang X, Roy A, Hochhaus A, et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol 5: 85-97, 2013.","DOI":"10.2147\/CPAA.S42796"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chuah C, Nakamae H, Kim DW, et al. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma 55: 2093-2100, 2014.","DOI":"10.3109\/10428194.2013.866663"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884, 2013.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Hassford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118: 686-692, 2011.","DOI":"10.1182\/blood-2010-12-319038"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rousselot P, Mollica L, Bouchet S, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol 194: 393-402, 2021.","DOI":"10.1111\/bjh.17654"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30: 1648-1671, 2016.","DOI":"10.1038\/leu.2016.104"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 126: 3207-3218, 2016.","DOI":"10.1172\/JCI86249"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Iurlo A, Galimberti S, Abruzzese E, et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol 97: 95-100, 2018.","DOI":"10.1007\/s00277-017-3144-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol 8: e902-e911, 2021.","DOI":"10.1016\/S2352-3026(21)00333-1"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1611-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:29:50Z","timestamp":1715574590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1611-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":18,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1611-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"article-number":"1611-23"}}